Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1282645 | 0.87 | OPRM1 (0.39) | OPRM1OPRK1OPRD1SLC22A1SLC6A4 | |
| SCHEMBL1282256 | 0.86 | ALDH1A1 (0.40) | OPRM1OPRK1OPRD1SLC22A1SLC6A4 | |
| SCHEMBL1282035 | 0.86 | OPRM1 (0.38) | OPRM1OPRK1OPRD1SLC22A1SLC6A4 | |
| SCHEMBL1708664 | 0.85 | CYP3A4 (0.44) | OPRK1CXCR3PANK3HSD17B10 | |
| SCHEMBL28247431 | 0.85 | CYP3A4 (0.50) | OPRM1OPRK1OPRD1SLC22A1SLC6A4 | |
| SCHEMBL15415179 | 0.85 | OPRM1 (0.37) | OPRM1OPRK1OPRD1SLC22A1SLC6A4 | |
| SCHEMBL1281858 | 0.85 | KDM4E (0.38) | OPRM1OPRK1OPRD1SLC22A1SLC6A4 | |
| SCHEMBL1282673 | 0.84 | OPRM1 (0.36) | OPRM1OPRK1OPRD1SLC22A1SLC6A4 | |
| SCHEMBL1282057 | 0.83 | CYP3A4 (0.40) | OPRM1OPRK1OPRD1SLC22A1SLC6A4 | |
| SCHEMBL1282416 | 0.83 | KDM4E (0.36) | OPRM1OPRK1OPRD1SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | SPERO GYRASE INC (US) | 2017-09-14 | — | — | US | disclosed |
| EP-2828257-B1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2017-07-26 | — | — | EP | disclosed |
| US-9604976-B2 | Antibacterial compounds | SPERO GYRASE, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150329530-A1 | ANTIBACTERIAL COMPUNDS | SPERO GYRASE, INC. | 2015-11-19 | — | — | US | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| EP-2828257-A1 | ANTIBACTERIAL COMPOUNDS | Biota Europe Ltd (GB) | 2015-01-28 | — | — | EP | disclosed |
| US-8906902-B2 | Antibacterial compounds | BIOTA EUROPE LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20130252938-A1 | Antibacterial Compounds | BIOTA EUROPE LTD. (GB) | 2013-09-26 | — | — | US | disclosed |
| WO-2013138860-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LIMITED (GB) | 2013-09-26 | — | — | WO | disclosed |
| EP-2625178-A1 | BACTERIA TOPOISOMERASE II INHIBITING 2-ETHYLCARBAMOYLAMINO-1, 3-BENZOTHIAZOL-5-YLS | Biota Europe Ltd (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
| WO-2012045124-A1 | BACTERIA TOPOISOMERASE II INHIBITING 2-ETHYLCARBAMOYLAMINO-1, 3-BENZOTHIAZOL-5-YLS | BIOTA EUROPE LTD (GB) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | STS, PGLS, PEPD | OPRM1 995/4885OPRK1 1724/4885OPRD1 931/4885 |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NISCH, LSS | OPRM1 2306/4885OPRK1 2429/4885OPRD1 2417/4885 |
| US-20150329530-A1 | ANTIBACTERIAL COMPUNDS | STS, PEPD, PGLS | OPRM1 1226/4885OPRK1 1556/4885OPRD1 668/4885 |
| US-20130252938-A1 | Antibacterial Compounds | STS, PGLS, PEPD | OPRM1 995/4885OPRK1 1724/4885OPRD1 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.